Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “selpercatinib” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 5
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 5 pipeline programs matching "selpercatinib" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

5 results for “selpercatinib” Back to intelligence hub

Search results

  1. Selpercatinib

    Eli Lilly and Company

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial
  2. SELPERCATINIB, SELPERCATINIB

    Wuhan Createrna Science and Technology Co., Ltd

    Male or female patients age 12 years or older with a locally advanced or metastatic solid tumor with evidence of a RET gene alteration in tumor and/or blood.

    phase 2 small molecule active

    1 trial
  3. Selpercatinib

    Eli Lilly and Company

    Medullary Thyroid Cancer

    phase 2 small molecule active

    1 trial
  4. Selpercatinib Monotherapy

    United Therapeutics Europe Ltd

    Differentiated Thyroid Cancer

    phase 2 small molecule active

    1 trial
  5. SELPERCATINIB, SELPERCATINIB

    Eli Lilly Co.

    Non Small Cell Lung Cancer; Medullary Thyroid Cancer; Colon Cancer; Breast Cancer; Pancreatic Cancer; Papillary Thyroid Cancer; Other Solid Tumors With Evidence of Activating RET Alteration;

    approved small molecule active

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.